Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Sep;36(9):2039–2041. doi: 10.1128/aac.36.9.2039

In vitro susceptibility of Mycobacterium kansasii to clarithromycin.

J Biehle 1, S J Cavalieri 1
PMCID: PMC192433  PMID: 1416897

Abstract

The MICs of the macrolide clarithromycin for 31 clinical isolates of Mycobacterium kansasii were determined by three different methods. The methods employed were the proportion resistance method on 7H10 agar, the radiometric (BACTEC) method, and the T100 method of datum analysis. All methods gave similar results. The MICs were in a narrow range from 0.16 to 0.50 microgram/ml, with the MICs for 90% of isolates tested of 0.50 microgram/ml for the agar dilution and radiometric methods and 0.37 microgram/ml for the T100 method. The MBCs were determined for nine representative isolates by the radiometric broth method. The MBCs were equal to the MICs for four isolates, and the MBCs were twofold higher than the MICs for five isolates. Killing of 99.9% of the bacterial population was achieved at a clarithromycin concentration of 2.0 micrograms/ml for all nine isolates tested.

Full text

PDF
2039

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahn C. H., Lowell J. R., Ahn S. S., Ahn S., Hurst G. A. Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs. Rev Infect Dis. 1981 Sep-Oct;3(5):1028–1034. doi: 10.1093/clinids/3.5.1028. [DOI] [PubMed] [Google Scholar]
  2. Berlin O. G., Young L. S., Floyd-Reising S. A., Bruckner D. A. Comparative in vitro activity of the new macrolide A-56268 against mycobacteria. Eur J Clin Microbiol. 1987 Aug;6(4):486–487. doi: 10.1007/BF02013117. [DOI] [PubMed] [Google Scholar]
  3. Brown B. A., Wallace R. J., Jr, Onyi G. O., De Rosas V., Wallace R. J., 3rd Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother. 1992 Jan;36(1):180–184. doi: 10.1128/aac.36.1.180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Carpenter J. L., Parks J. M. Mycobacterium kansasii infections in patients positive for human immunodeficiency virus. Rev Infect Dis. 1991 Sep-Oct;13(5):789–796. doi: 10.1093/clinids/13.5.789. [DOI] [PubMed] [Google Scholar]
  5. Dabernat H., Delmas C., Seguy M., Fourtillan J. B., Girault J., Lareng M. B. The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae, determined by in-vitro and serum bactericidal tests. J Antimicrob Chemother. 1991 Feb;27 (Suppl A):19–30. doi: 10.1093/jac/27.suppl_a.19. [DOI] [PubMed] [Google Scholar]
  6. Dautzenberg B., Truffot C., Legris S., Meyohas M. C., Berlie H. C., Mercat A., Chevret S., Grosset J. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):564–569. doi: 10.1164/ajrccm/144.3_Pt_1.564. [DOI] [PubMed] [Google Scholar]
  7. Fernandes P. B., Hardy D. J., McDaniel D., Hanson C. W., Swanson R. N. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother. 1989 Sep;33(9):1531–1534. doi: 10.1128/aac.33.9.1531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gorzynski E. A., Gutman S. I., Allen W. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. Antimicrob Agents Chemother. 1989 Apr;33(4):591–592. doi: 10.1128/aac.33.4.591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hardy D. J., Guay D. R., Jones R. N. Clarithromycin, a unique macrolide. A pharmacokinetic, microbiological, and clinical overview. Diagn Microbiol Infect Dis. 1992 Jan;15(1):39–53. doi: 10.1016/0732-8893(92)90055-x. [DOI] [PubMed] [Google Scholar]
  10. Hardy D. J., Swanson R. N., Rode R. A., Marsh K., Shipkowitz N. L., Clement J. J. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother. 1990 Jul;34(7):1407–1413. doi: 10.1128/aac.34.7.1407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Heifets L. Qualitative and quantitative drug-susceptibility tests in mycobacteriology. Am Rev Respir Dis. 1988 May;137(5):1217–1222. doi: 10.1164/ajrccm/137.5.1217. [DOI] [PubMed] [Google Scholar]
  12. Inderlied C. B., Young L. S., Yamada J. K. Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods. Antimicrob Agents Chemother. 1987 Nov;31(11):1697–1702. doi: 10.1128/aac.31.11.1697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lillo M., Orengo S., Cernoch P., Harris R. L. Pulmonary and disseminated infection due to Mycobacterium kansasii: a decade of experience. Rev Infect Dis. 1990 Sep-Oct;12(5):760–767. doi: 10.1093/clinids/12.5.760. [DOI] [PubMed] [Google Scholar]
  14. Naik S., Ruck R. In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex. Antimicrob Agents Chemother. 1989 Sep;33(9):1614–1616. doi: 10.1128/aac.33.9.1614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Olsson-Liljequist B., Hoffman B. M. In-vitro activity of clarithromycin combined with its 14-hydroxy metabolite A-62671 against Haemophilus influenzae. J Antimicrob Chemother. 1991 Feb;27 (Suppl A):11–17. doi: 10.1093/jac/27.suppl_a.11. [DOI] [PubMed] [Google Scholar]
  16. Pezzia W., Raleigh J. W., Bailey M. C., Toth E. A., Silverblatt J. Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev Infect Dis. 1981 Sep-Oct;3(5):1035–1039. doi: 10.1093/clinids/3.5.1035. [DOI] [PubMed] [Google Scholar]
  17. Truffot-Pernot C., Ji B., Grosset J. Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. Antimicrob Agents Chemother. 1991 Aug;35(8):1677–1678. doi: 10.1128/aac.35.8.1677. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES